Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SLS

SLS - SELLAS Life Sciences Group Inc Stock Price, Fair Value and News

$3.96-0.44 (-10.00%)
Market Closed

7/100

SLS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

7/100

SLS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$3.41

Target 3M

$3.83

Target 6M

$3.62

SLS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SLS Price Action

Last 7 days

-13.5%

Last 30 days

18.2%

Last 90 days

107.3%

Trailing 12 Months

238.5%

SLS RSI Chart

SLS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SLS Valuation

Market Cap

564.1M

Price/Earnings (Trailing)

-21.74

Price/Sales (Trailing)

212.24

EV/EBITDA

-4.1

Price/Free Cashflow

-18.4

SLS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$3.41

Target 3M

$3.83

Target 6M

$3.62

SLS Fundamentals

SLS Revenue

Revenue (TTM)

1.0M

SLS Earnings

Earnings (TTM)

-25.9M

Earnings Growth (Yr)

4.46%

Earnings Growth (Qtr)

-2.88%

SLS Profitability

Operating Margin

-58.60%

EBT Margin

-4130.10%

Return on Equity

-56.85%

Return on Assets

-50.32%

Free Cashflow Yield

-5.43%

SLS Investor Care

Shares Dilution (1Y)

102.38%

Diluted EPS (TTM)

-0.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20222.9M1.0M1.0M1.0M
20213.3M4.8M6.2M7.6M
20200001.9M
20159.9M10.9M00
20149.3M9.3M9.3M9.3M
201307.0M7.4M9.3M
20120000
20110000
20100000
Get all data in R, Python etc through our Historical Stock Data APIs

About SELLAS Life Sciences Group Inc

SLS
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.
 CEO
 WEBSITEsellaslifesciences.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES17

SELLAS Life Sciences Group Inc Frequently Asked Questions

SLS is the stock ticker symbol of SELLAS Life Sciences Group Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of SELLAS Life Sciences Group Inc is 564.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check SLS's fair value in chart for subscribers.

The fair value guage provides a quick view whether SLS is over valued or under valued. Whether SELLAS Life Sciences Group Inc is cheap or expensive depends on the assumptions which impact SELLAS Life Sciences Group Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SLS.

As of Wed Jan 28 2026, SLS's PE ratio (Price to Earnings) is -21.74 and Price to Sales (PS) ratio is 212.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SLS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, SELLAS Life Sciences Group Inc has provided -0.574 (multiply by 100 for percentage) rate of return.